Healthcare insurance companies face a dire future with Alzheimer's Disease (AD) looming large. The industry expends tens of billions of dollars on advanced AD treatment and that needs to change—it's stuck reacting with knee-jerk fixes that fail. Zentara, a groundbreaking new company, is pushing to steer the conversation away from these ineffective tactics to cutting-edge AD prevention using affordable blood-based biomarkers. To fund this new prevention plan, the company has rolled out a new financial instrument called AD Bonds to address the economic side of things.
Over the years, AD has grown into a massive problem for U.S. insurers, and instead of detecting the disease early on, they lean on half-measures that don't fix anything—like dodging diagnostics while costs surge later. The big reason for this crisis is the steep costs tied to diagnosing AD early: a PET scan can cost as much as $8,000 from an insurer's pocket. With Zentara's innovative blood-based marker tech, insurance companies only need to pay $350 for each test and use targeted PET scans for the ones who really need them.
